Newland Pharmaceutical Co., Ltd.

Primary objective: To investigate the pharmacokinetic parameters and relative bioavailability of ruxolitinib phosphate tablets (20 mg) manufactured by Xintiandi Pharmaceutical Co., Ltd., as the test formulation, and ruxolitinib phosphate tablets (Jakavi, 20 mg) manufactured by Novartis Europharm Limited, as the reference formulation, under fasting and postprandial administration, and to evaluate the bioequivalence of the two formulations. Secondary objective: To evaluate the safety of ruxolitinib phosphate tablets (20 mg) in healthy Chinese subjects.

Primary Objective: To evaluate the bioequivalence of the test formulation oseltamivir phosphate capsules (75 mg, manufactured by Shandong Yaoshi Pharmaceutical Co., Ltd. (manufactured under contract with Xintiandi Pharmaceutical Co., Ltd.)) and the reference formulation oseltamivir phosphate capsules (75 mg, licensee: Roche Pharma (Schweiz) AG, trade name: Tamiflu®) in Chinese health study participants, using pharmacokinetic parameters as the primary endpoint. Secondary Objective: To observe the safety of the test formulation oseltamivir phosphate capsules and the reference formulation oseltamivir phosphate capsules in Chinese health study participants.

1. Moxifloxacin hydrochloride tablets (specification: 0.4 g) from Xintiandi Pharmaceutical Co., Ltd. as the test preparation and moxifloxacin hydrochloride tablets (specification: 0.4 g, trade name: Baifule®) from Bayer Vital GmbH as the reference preparation were used to evaluate the bioequivalence of the two preparations in the fasting and postprandial state through a single-center, randomized, open, single-dose, two-preparation, two-period crossover design. 2. Observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.